Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial

AIMS: The SHIFT trial showed that ivabradine reduced heart rate (HR) and the risk of cardiovascular outcomes. Concerns remain over the efficacy and safety of ivabradine on heart failure (HF) due to Chagas disease (ChD). We therefore conducted a post hoc analysis of the SHIFT trial to investigate the...

Descripción completa

Detalles Bibliográficos
Autores principales: Bocchi, Edimar Alcides, Rassi, Salvador, Guimarães, Guilherme Veiga
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5933959/
https://www.ncbi.nlm.nih.gov/pubmed/29266804
http://dx.doi.org/10.1002/ehf2.12240

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5933959/
https://www.ncbi.nlm.nih.gov/pubmed/29266804
http://dx.doi.org/10.1002/ehf2.12240

Ejemplares similares